Meta-analysis confirms nephroprotective benefits of ERAs
A recent research study, conducted by Shi and colleagues and published in the Clinical Journal of the American Society of …
Post
-
-
UK DRI announces trial of blood test for Alzheimer’s diagnosis
The UK Dementia Research Institute (DRI) has announced an international research study, which is underway to assess whether a finger-prick …
-
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
D3 Bio has received the US Food and Drug Administration (FDA) clearance for two investigational new drug (IND) applications, enabling …
-
2026: The time for AI to really deliver
In 2026, clinical trial design will be reshaped by artificial intelligence (AI)-powered simulation and richer clinical and real-world data. Improvements …
-
Nxera reports positive outcomes for daridorexant Phase III insomnia study
Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50mg, aimed at treating insomnia in …
-
JPM26: Immunocore Signals Entry into Type 1 Diabetes
At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on 14th January 2026, Immunocore outlined 2026 strategic priorities …
-
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its …
-
Clinical Trials Arena Excellence Awards 2025: Incannex Healthcare
Incannex Healthcare (Nasdaq: IXHL), a clinical‑stage pharmaceutical development company focused on developing novel therapies for conditions with limited effective treatment …
-
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK) showed over 15 …
-
OrsoBio announces clinical trial progress for TLC-2716 metabolic therapy
OrsoBio has announced the publication in Nature Medicine of Phase I clinical trial data for TLC-2716, an oral liver-targeted inverse …
-
Genmab reports top line results in Phase III DLBCL trial
Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival …
-
Speech biomarkers offer new lease of life to patient experience and trial retention
Biomarkers remain a critical measurement in almost every clinical trial, with this type of data facilitating the accurate characterisation of …
-
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining …
-
The advantages of a platform approach in clinical trial data management
Clinical trials are producing more data than ever before, drawing from vast and diverse datasets that must be cleaned and …
-
Ocugen sets sights on Phase III after GA gene therapy win
Ocugen has posted positive results for its lead investigational gene therapy, OCU410, in geographic atrophy (GA) secondary to dry age-related …
